But an existing injectable drug might make these attacks much less frightening, a new clinical trial has shown. The already-approved drug for asthma could replace steroid medications as a means of ...

Asthma affects more than 260M people worldwide and nearly 28M people in the U.S. alone, where, on average, 10 people die from attacks of the chronic disease each day.

The first new treatment ... severe form of the disease. The monoclonal antibody specifically targets white blood cells that can invade the lungs of people with so-called eosinophilic asthma ...

A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

More information: Chun-Tse Hung et al, Cost-related non-adherence to medications among adults with asthma in the U.S., 2011–2022, Thorax (2024).DOI: 10.1136/thorax-2024-221778 Emily L Graul et ...

This form of aversion has been noticed among the patients with asthma and AD, but it can be present with other conditions including CS medication within the treatment plan. Adherence to the ...

Plan on slippery road conditions ... The already-approved drug for asthma could replace steroid medications as a means of quelling asthma and COPD flare-ups, researchers report.

Benralizumab, the first new treatment for asthma attacks and chronic obstructive pulmonary disease (COPD) in 50 years, was initially approved by US and EU regulators in 2017. It was specifically ...

Factors that were associated with cost-related medication nonadherence included demographics and comorbidities. (HealthDay News) — For adults with asthma, the prevalence of cost-related ...